Post by shahadat560 on Jan 16, 2024 6:02:13 GMT
The conclusions on the effectiveness of the first American vaccine against Covid-19 could be known before the November 3 elections , in which Donald Trump is at stake for re-election, the country's main epidemiologist, Anthony Fauci, indicated this Monday.
The vaccine developed by the biotechnology company Moderna together with the National Institutes of Health (NIH) of the United States began its phase 3 of testing this Monday, making it the first outside of China to reach this critical point to verify its effectiveness and safety. before being distributed en masse.
"It is a world record for us to have been able to go from sequencing (of the SARS-CoV-2 virus) to phase 3 of a vaccine in such a short time. It had never been done before," explained Fauci, who assured that this process, which lasted about six months, has not compromised the scientific rigor or safety of the trials.
"IT COULD BE SOONER." The director of the National Country Email List Institute of Infectious Diseases said that the first conclusions on whether the vaccine is likely to be produced and distributed among the population may come "at the beginning of November, but it could be earlier." "It is very difficult to put your finger on a date. Today is the first day and we will have to see in the coming weeks if there is an increase (in the immune response) after 28 days (when the second dose will be administered)," Fauci said. who does not rule out that the first conclusions on immunity will be known sooner.
The dates of presentation of these results are essential. If they occur in October, they could fully enter the final stretch of the electoral campaign and give the Trump Administration arguments in favor of the re-election of the Republican, whose response to the pandemic has been widely criticized for having ignored the seriousness of the situation.
Fauci stated that there are important variables, such as the number of volunteers who join the phase 3 tests of the vaccine, as well as their origin, since they must represent the regions and population segments with the highest incidence of infections.
At 6:45 a.m. this Monday (12:45 GMT) a person in Savannah (Georgia) was the first to receive the Moderna vaccine. In the coming weeks it should be administered to around 30,000 volunteers. Half will receive a placebo of a saline solution that will allow a statistical contrast to measure the immune response.
The director of the NIH, Francis Collins, pointed out that experts will determine which groups are priority to receive the vaccine first, although he highlighted health personnel, older adults, people with previous illnesses, African Americans and Hispanics.
The vaccine developed by the biotechnology company Moderna together with the National Institutes of Health (NIH) of the United States began its phase 3 of testing this Monday, making it the first outside of China to reach this critical point to verify its effectiveness and safety. before being distributed en masse.
"It is a world record for us to have been able to go from sequencing (of the SARS-CoV-2 virus) to phase 3 of a vaccine in such a short time. It had never been done before," explained Fauci, who assured that this process, which lasted about six months, has not compromised the scientific rigor or safety of the trials.
"IT COULD BE SOONER." The director of the National Country Email List Institute of Infectious Diseases said that the first conclusions on whether the vaccine is likely to be produced and distributed among the population may come "at the beginning of November, but it could be earlier." "It is very difficult to put your finger on a date. Today is the first day and we will have to see in the coming weeks if there is an increase (in the immune response) after 28 days (when the second dose will be administered)," Fauci said. who does not rule out that the first conclusions on immunity will be known sooner.
The dates of presentation of these results are essential. If they occur in October, they could fully enter the final stretch of the electoral campaign and give the Trump Administration arguments in favor of the re-election of the Republican, whose response to the pandemic has been widely criticized for having ignored the seriousness of the situation.
Fauci stated that there are important variables, such as the number of volunteers who join the phase 3 tests of the vaccine, as well as their origin, since they must represent the regions and population segments with the highest incidence of infections.
At 6:45 a.m. this Monday (12:45 GMT) a person in Savannah (Georgia) was the first to receive the Moderna vaccine. In the coming weeks it should be administered to around 30,000 volunteers. Half will receive a placebo of a saline solution that will allow a statistical contrast to measure the immune response.
The director of the NIH, Francis Collins, pointed out that experts will determine which groups are priority to receive the vaccine first, although he highlighted health personnel, older adults, people with previous illnesses, African Americans and Hispanics.